_id
691b0fa13c536f8df2318a4f
Ticker
ALNEV.PA
Name
Neovacs S.A.
Exchange
PA
Address
3-5, Impasse Reille, Paris, France, 75014
Country
France
Sector
Healthcare
Industry
Biotechnology
Currency
EUR
Website
https://www.neovacs.com
Description
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.
Last Close
1.8
Volume
291384
Current Price
0.0088
Change
-99.46666666666665
Last Updated
2025-11-27T11:39:50.931Z
Image
https://logo.clearbit.com/www.neovacs.com
Ipo Date
-
Market Cap
8245
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2024-12-31
Revenue
41044
Cost Of Revenue
3059527
Gross Profit
-3018483
Operating Expenses
38245
Operating Income
-3056726
Interest Expense
20395843
Pretax Income
-2506123
Net Income
-1923413
Eps
-11.02153981915491
Dividends Per Share
-
Shares Outstanding
476625
Income Tax Expense
-582710
EBITDA
17986002
Operating Margin
-7447.436896988597
Total Other Income Expense Net
550603
Cash
435441
Short Term Investments
8
Receivables
513704
Inventories
-
Total Current Assets
2506096
Property Plant Equipment
414794
Total Assets
22070623
Payables
2275110
Short Term Debt
230367
Long Term Debt
0
Total Liabilities
4008459
Equity
18062164
Depreciation
96286
Change In Working Capital
1543415
Cash From Operations
-661210
Capital Expenditures
11240
Cash From Investing
-264164
Cash From Financing
1129212
Net Change In Cash
203836
PE
-
PB
0.00008502431934512388
ROE
-10.648851377941204
ROA
-8.714810633120777
FCF
-672450
Fcf Percent
-16.383637072410096
Piotroski FScore
1
Health Score
34
Deep Value Investing Score
7
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
4
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
5.5
Quarters > 0 > quarter
2024-12-31
Quarters > 0 > income Statement > revenue
41044
Quarters > 0 > income Statement > cost Of Revenue
3059527
Quarters > 0 > income Statement > gross Profit
-3018483
Quarters > 0 > income Statement > operating Expenses
38245
Quarters > 0 > income Statement > operating Income
-3056726
Quarters > 0 > income Statement > interest Expense
20395843
Quarters > 0 > income Statement > pretax Income
-2506123
Quarters > 0 > income Statement > net Income
-1923413
Quarters > 0 > income Statement > eps
-11.02153981915491
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
174514
Quarters > 0 > income Statement > income Tax Expense
-582710
Quarters > 0 > income Statement > EBITDA
17986002
Quarters > 0 > income Statement > operating Margin
-7447.436896988597
Quarters > 0 > income Statement > total Other Income Expense Net
550603
Quarters > 0 > balance Sheet > cash
435441
Quarters > 0 > balance Sheet > short Term Investments
8
Quarters > 0 > balance Sheet > receivables
513704
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
2506096
Quarters > 0 > balance Sheet > property Plant Equipment
414794
Quarters > 0 > balance Sheet > total Assets
22070623
Quarters > 0 > balance Sheet > payables
2275110
Quarters > 0 > balance Sheet > short Term Debt
230367
Quarters > 0 > balance Sheet > long Term Debt
0
Quarters > 0 > balance Sheet > total Liabilities
4008459
Quarters > 0 > balance Sheet > equity
18062164
Quarters > 0 > cash Flow > net Income
-1923413
Quarters > 0 > cash Flow > depreciation
96286
Quarters > 0 > cash Flow > change In Working Capital
1543415
Quarters > 0 > cash Flow > cash From Operations
-661210
Quarters > 0 > cash Flow > capital Expenditures
11240
Quarters > 0 > cash Flow > cash From Investing
-264164
Quarters > 0 > cash Flow > cash From Financing
1129212
Quarters > 0 > cash Flow > net Change In Cash
203836
Quarters > 0 > ratios > PE
-11.02153981915491
Quarters > 0 > ratios > PB
0.00008502431934512388
Quarters > 0 > ratios > ROE
-10.648851377941204
Quarters > 0 > ratios > ROA
-8.714810633120777
Quarters > 0 > ratios > FCF
-672450
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-16.383637072410096
Quarters > 0 > health Score
34
Quarters > 1 > quarter
2024-06-30
Quarters > 1 > income Statement > revenue
250263
Quarters > 1 > income Statement > cost Of Revenue
3364955
Quarters > 1 > income Statement > gross Profit
-3114692
Quarters > 1 > income Statement > operating Expenses
592922
Quarters > 1 > income Statement > operating Income
-3707618
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-31442325
Quarters > 1 > income Statement > net Income
-30990996
Quarters > 1 > income Statement > eps
-33192.66550280077
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
933.67
Quarters > 1 > income Statement > income Tax Expense
-451329
Quarters > 1 > income Statement > EBITDA
-31346600
Quarters > 1 > income Statement > operating Margin
-1481.4886739150413
Quarters > 1 > income Statement > total Other Income Expense Net
-27734707
Quarters > 1 > balance Sheet > cash
231605
Quarters > 1 > balance Sheet > short Term Investments
6
Quarters > 1 > balance Sheet > receivables
486760
Quarters > 1 > balance Sheet > inventories
28829
Quarters > 1 > balance Sheet > total Current Assets
2830496
Quarters > 1 > balance Sheet > property Plant Equipment
499627
Quarters > 1 > balance Sheet > total Assets
43921298
Quarters > 1 > balance Sheet > payables
2492942
Quarters > 1 > balance Sheet > short Term Debt
480623
Quarters > 1 > balance Sheet > long Term Debt
0
Quarters > 1 > balance Sheet > total Liabilities
25290961
Quarters > 1 > balance Sheet > equity
18630337
Quarters > 1 > cash Flow > net Income
-30990996
Quarters > 1 > cash Flow > depreciation
95726
Quarters > 1 > cash Flow > change In Working Capital
-1001188
Quarters > 1 > cash Flow > cash From Operations
-2940010
Quarters > 1 > cash Flow > capital Expenditures
68470
Quarters > 1 > cash Flow > cash From Investing
1714511
Quarters > 1 > cash Flow > cash From Financing
570023
Quarters > 1 > cash Flow > net Change In Cash
-655482
Quarters > 1 > ratios > PE
-33192.66550280077
Quarters > 1 > ratios > PB
4.410170358163677e-7
Quarters > 1 > ratios > ROE
-166.3469426237432
Quarters > 1 > ratios > ROA
-70.56029172908323
Quarters > 1 > ratios > FCF
-3008480
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-12.0212736201516
Quarters > 1 > health Score
24
Quarters > 2 > quarter
2023-12-31
Quarters > 2 > income Statement > revenue
431041
Quarters > 2 > income Statement > cost Of Revenue
3574631
Quarters > 2 > income Statement > gross Profit
-3143590
Quarters > 2 > income Statement > operating Expenses
84760
Quarters > 2 > income Statement > operating Income
-3228346
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-5035587
Quarters > 2 > income Statement > net Income
-4460395
Quarters > 2 > income Statement > eps
-126823.85555871481
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
35.17
Quarters > 2 > income Statement > income Tax Expense
-575193
Quarters > 2 > income Statement > EBITDA
-4950228
Quarters > 2 > income Statement > operating Margin
-748.9649476499915
Quarters > 2 > income Statement > total Other Income Expense Net
-1807241
Quarters > 2 > balance Sheet > cash
887087
Quarters > 2 > balance Sheet > short Term Investments
0
Quarters > 2 > balance Sheet > receivables
2779415
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
3838769
Quarters > 2 > balance Sheet > property Plant Equipment
526665
Quarters > 2 > balance Sheet > total Assets
52562415
Quarters > 2 > balance Sheet > payables
1981833
Quarters > 2 > balance Sheet > short Term Debt
586
Quarters > 2 > balance Sheet > long Term Debt
650000
Quarters > 2 > balance Sheet > total Liabilities
3717868
Quarters > 2 > balance Sheet > equity
43821471
Quarters > 2 > cash Flow > net Income
-4460395
Quarters > 2 > cash Flow > depreciation
85358
Quarters > 2 > cash Flow > change In Working Capital
1892001
Quarters > 2 > cash Flow > cash From Operations
1474318
Quarters > 2 > cash Flow > capital Expenditures
150448
Quarters > 2 > cash Flow > cash From Investing
-8260484
Quarters > 2 > cash Flow > cash From Financing
1481202
Quarters > 2 > cash Flow > net Change In Cash
-5304964
Quarters > 2 > ratios > PE
-126823.85555871481
Quarters > 2 > ratios > PB
7.0626565685118155e-9
Quarters > 2 > ratios > ROE
-10.178560642110805
Quarters > 2 > ratios > ROA
-8.485901951042395
Quarters > 2 > ratios > FCF
1323870
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
3.071331961460743
Quarters > 2 > health Score
53
Quarters > 3 > quarter
2023-06-30
Quarters > 3 > income Statement > revenue
102371
Quarters > 3 > income Statement > cost Of Revenue
3713139
Quarters > 3 > income Statement > gross Profit
-3610768
Quarters > 3 > income Statement > operating Expenses
68431
Quarters > 3 > income Statement > operating Income
-3679203
Quarters > 3 > income Statement > interest Expense
1223912
Quarters > 3 > income Statement > pretax Income
-4584619
Quarters > 3 > income Statement > net Income
-4283055
Quarters > 3 > income Statement > eps
-428305500
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
0.01
Quarters > 3 > income Statement > income Tax Expense
-301564
Quarters > 3 > income Statement > EBITDA
-3282158
Quarters > 3 > income Statement > operating Margin
-3593.9895087475948
Quarters > 3 > income Statement > total Other Income Expense Net
-905416
Quarters > 3 > balance Sheet > cash
1741906
Quarters > 3 > balance Sheet > short Term Investments
4450145
Quarters > 3 > balance Sheet > receivables
1709687
Quarters > 3 > balance Sheet > inventories
423517
Quarters > 3 > balance Sheet > total Current Assets
8466557
Quarters > 3 > balance Sheet > property Plant Equipment
458883
Quarters > 3 > balance Sheet > total Assets
50980517
Quarters > 3 > balance Sheet > payables
2806287
Quarters > 3 > balance Sheet > short Term Debt
1500000
Quarters > 3 > balance Sheet > long Term Debt
3268700
Quarters > 3 > balance Sheet > total Liabilities
5951712
Quarters > 3 > balance Sheet > equity
45028805
Quarters > 3 > cash Flow > net Income
-4283055
Quarters > 3 > cash Flow > depreciation
78552
Quarters > 3 > cash Flow > change In Working Capital
-330486
Quarters > 3 > cash Flow > cash From Operations
-3387483
Quarters > 3 > cash Flow > capital Expenditures
52937
Quarters > 3 > cash Flow > cash From Investing
-2818245
Quarters > 3 > cash Flow > cash From Financing
5312119
Quarters > 3 > cash Flow > net Change In Cash
-9439479
Quarters > 3 > ratios > PE
-428305500
Quarters > 3 > ratios > PB
1.9543045834771764e-12
Quarters > 3 > ratios > ROE
-9.511811383846407
Quarters > 3 > ratios > ROA
-8.40135654175496
Quarters > 3 > ratios > FCF
-3440420
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-33.607369274501565
Quarters > 3 > health Score
34
Valuation > metrics > PE
-11.02153981915491
Valuation > metrics > PB
0.00008502431934512388
Valuation > final Score
70
Valuation > verdict
100.0% Undervalued
Profitability > metrics > ROE
-10.648851377941204
Profitability > metrics > ROA
-76.74937432564435
Profitability > metrics > Net Margin
-46.86222103108859
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.2219257338157266
Risk > metrics > Interest Coverage
-0.14987004949979268
Risk > final Score
59
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.0002470587437042
Liquidity > metrics > Quick Ratio
1.0002470587437042
Liquidity > final Score
75
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-125
Prev Risks > 1
-91
Prev Risks > 2
48
Prev Liquidities > 0
57
Prev Liquidities > 1
98
Prev Liquidities > 2
99
Updated At
2026-01-20T23:09:00.492Z
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.
Stock Price
€0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AALNEV.PA down 99.6% to €0.0072 on EURONEXT: check cash and trial risks Meyka
Read more →ALNEV.PA Neovacs (EURONEXT) €0.009 after-hours 12 Jan 2026: watch catalysts Meyka
Read more →Showing 2 of 4
(Last Updated 2024-12-31)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Neovacs S.A.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2024-12-31)
(Last Updated 2024-12-31)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2024-12-31)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2024-12-31)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.